Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005–2014)

Maïna L’Azoua,†, Jade Assouka,‡, Karen Fanouillere, Eric Pellenvauxc, Matthew Bonaparted, Alain Bouckenooghe, Carina Frago, Fernando Noriegad, Betzana Zambranof, R. Leon Ochiais, Bruno Guya, and Nicholas Jacksonb

Introduction

Dengue, a mosquito-borne viral disease, has rapidly spread across the tropical and subtropical regions of the world in recent decades. The disease is considered to be endemic and a major public health concern in over 120 countries in the Asia-Pacific region, Africa, and Latin America (including the Caribbean). Worldwide, an estimated 390 million dengue infections occur every year, of which around 100 million are associated with clinical manifestations and the remainder asymptomatic. Clinical manifestations range from mild febrile illness to severe disease requiring hospitalization and, in some cases, leading to fatalities. There are four genetically divergent dengue virus serotypes with antigenic differences. Infection with one serotype is generally believed to produce durable, even life-long, homotypic immunity against that same serotype, but generates initial partial and transient cross-protection against the other serotypes, allowing sequential dengue infections with other serotypes in an individual.

Although dengue is a notifiable disease in many countries, constraints inherent in public health surveillance systems and challenges specific to dengue do not allow dengue cases to be fully captured. These constraints and challenges are related to the non-specific nature and wide spectrum of dengue illness, and in part, to the lack of uniform case definitions, diagnostic ascertainment, laboratory capabilities and capacity, as well as a reliance on diverse public health practices and healthcare professionals for disease notification. Consequently, the true number of dengue cases is probably substantially underreported. Moreover, variability in underreporting both within and between countries affects the interpretation and comparability of the disease profile and rates from different public health surveillance systems.

Received 9 February 2018; revised 23 March 2018; editorial decision 4 April 2018; accepted 6 April 2018

Dengue seroprevalence data in the literature is limited and the available information is difficult to compare between studies because of the varying survey designs and methods used. We assessed dengue seropositivity across 14 countries using data from 15 trials conducted during the development of a tetravalent dengue vaccine between October 2005 and February 2014. Participants’ dengue seropositivity (n=8592) was determined from baseline (before vaccination) serum samples at two centralized laboratories with the plaque reduction neutralization test (PRNT50). Seropositivity rates generally increased with age in endemic settings. Although seropositivity rates varied across geographical areas, between countries, and within countries by region, no major differences were observed for given age groups between the two endemic regions, Latin America and Asia-Pacific. Seropositivity rates were generally stable over time. The proportion of participants who had only experienced primary infection tended to be higher in younger children than adolescents/adults. These results will help inform and guide dengue control strategies in the participating countries.

Keywords: Dengue, PRNT, Seropositivity, Seroprevalence

© The Author(s) 2018. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
As there is a large reservoir of undetected dengue infections, asymptomatic and underreported cases, serological data are essential in determining the true extent of dengue exposure, and the role of both symptomatic and asymptomatic infections in dengue transmission dynamics. Recent WHO SAGE recommendations and a subsequent WHO position paper on dengue suggested that seroprevalence data could be used to help define age groups and populations for dengue vaccine vaccination with the licensed Sanofi Pasteur’s live, attenuated, tetravalent dengue vaccine (CYD-TDV). However, robust age-stratified seroprevalence data are sometimes not available, or if available, generated with non-standardized laboratory methods, which makes generalization or comparison of the limited available data beyond the locality where the data were gathered questionable.

Enzyme-linked immunosorbent assays (ELISAs) for anti-dengue IgG or IgM antibodies are widely used to assess dengue seroprevalence. These have several limitations including cross-reactivity with other flaviviruses, such as yellow fever, Japanese encephalitis and Zika, and their inability to distinguish between the different infecting serotypes. The plaque reduction neutralization test (PRNT) is a sensitive and specific test for detecting neutralizing antibodies against dengue. It is also the recommended test for assessing immunogenicity in dengue vaccine trials. However, the PRNT is costlier and technically more demanding than ELISA assessment and, as such, is typically not used for routine surveillance purposes.

The PRNT50 was extensively used during the clinical development of the Sanofi Pasteur’s CYD-TDV to determine baseline dengue serostatus and vaccine immunogenicity. Here we present an unprecedented summary of dengue seropositivity data across a range of age groups, countries and time periods, based on pre-vaccination PRNT50 data from trials undertaken with CYD-TDV.

Materials and methods

Studies and study participants

During the development of CYD-TDV, between October 2005 and February 2014, 24 trials were undertaken across 15 countries. Enrolled participants were healthy and within the age range 12 months to 60 years (Table 1). Studies that excluded participants based on their baseline dengue status (assessed or self-reported; n=7) were excluded from the current analysis to limit selection bias. Two additional studies were excluded because of database incompatibility; CYD01 and CYD02 (the earliest studies) were excluded because their databases were in a different ‘older format’ that was not compatible with that used in the other databases for the latter studies. Therefore, our analysis was based on data from 15 studies across 14 countries (Table 1). Participants were excluded from the selected studies if they had febrile illness within the 7 days preceding inclusion, congenital or acquired immunodeficiency, or had received another vaccine in the 4 weeks before inclusion. Other specific inclusion and exclusion criteria have been described in the corresponding publications (citations listed in Table 1).

All studies included in our analysis were performed in accordance with the Declaration of Helsinki and the International Conference on Harmonization—Good Clinical Practice. Study protocols and amendments were approved by the individual review board/independent ethics committee for each participating site. All participants or their parents/guardians provided informed written consent.

Laboratory tests

The participants’ dengue serostatus was assessed at baseline using a validated PRNT50 according to World Health Organization guideline recommendations. For the phase I studies, several challenge viruses were considered for each serotype, before one of each serotype was selected for subsequent PRNT50 use in phase II/III studies. Only results obtained with similar challenge viruses (i.e. DENV-1 strain PUO-359, DENV-2 strain PUO-218, DENV-3 strain PaH881/88 and DENV-4 strain 1228) in phase I through to phases II and III are included in our report. Titers were calculated and expressed as the highest reciprocal serum dilution (1/dil) that reduced the mean plaque count by 50% compared with the virus input control. The detection threshold for the assay was a neutralizing antibody titer of 1:10 dil. The PRNT50 was performed in two different laboratories: Sanofi Pasteur’s Global Clinical Immunology laboratory (Swiftwater, PA, USA) and the Center for Vaccine Development at Mahidol University (Bangkok, Thailand). Both sites followed the same protocols and concordance was established between the two sites.

Dengue seropositivity was defined as PRNT50 titer ≥10 1/dil to at least one serotype. Primary dengue infection was defined as PRNT50 titer ≥10 1/dil to only one dengue virus serotype (i.e. a monotypic PRNT50 profile).

Statistical methods

All analyses were descriptive. Outcomes of interest were dengue seropositivity and the proportion of participants who had only experienced primary infection. We assumed that the proportion of participants seropositive for only one serotype would approximate to the primary dengue infection rate. These outcomes were described in terms of the number and percentage of participants, overall and by age group, and by country and study. Age groups defined for the analyses were <2 years, 2–8, 9–17, 18–45 and ≥46 years. Binomial approximation from the Clopper–Pearson method was used to calculate 95% CI. Analyses were carried out using Stata v14 statistical software (StatCorp LP, College Station, TX, USA) or R statistical package v3.2.0 (R Development Core Team, Vienna, Austria).

Results

Study participant characteristics

Data for the <2-year age group were available for the Philippines, Mexico, Peru and Colombia. Data for both the 2–8- and 9–17-year age groups were available for several Asia-Pacific (the Philippines, Thailand, Vietnam, Malaysia, Indonesia and Singapore) and Latin American countries (Mexico and Peru); for 9–17-year-olds, data were additionally available for Colombia, Puerto Rico, Brazil and Honduras. Data for the 18–45-year age
Table 1. Summary of studies from the clinical development of the live, attenuated, tetravalent dengue vaccine that were considered for inclusion in this integrated summary; those excluded are highlighted as ‘not included’ in the Analyses column. The reason for exclusion of some studies from the current analysis (n=7) was to limit selection bias because these recruited participants were based on their baseline dengue status (assessed or self-reported) and thus, not representative of their respective populations in their countries.

| Study (CYD ID) | Immunosubset (planned) | Immunosubset (analysed) | Country | City/municipality | Age group | Screening period | Study design | Analyses | References |
|----------------|-------------------------|-------------------------|---------|-------------------|-----------|-----------------|-------------|----------|------------|
| CYD01          | 56                      | 56                      | USA     | Springfield       | 18–49 y   | 03/2002–06/2002 | Mono        | Not included | Guirakhoo et al., Hum Vaccin 2006 |
| CYD02          | 99                      | 99                      | USA     | Springfield       | 18–40 y   | 11/2003–11/2004 | Mono        | Not included | Data on file |
| CYD04          | 66                      | 66                      | USA     | Springfield       | 18–45 y   | 10/2005–02/2007 | Mono        | Included     | Morrisson et al., J Infect Dis, 2010 |
| CYD05          | 126                     | 126                     | Philippines | Muntinlupa | 2–45 y   | 03/2006–10/2007 | Mono        | Not included | Capeding et al., Vaccine, 2011 |
| CYD06          | 126                     | 126                     | Mexico  | Tixapan Valle del Chalco | 2–45 y | 01/2006–08/2007 | Mono        | Included     | Poo et al., Pediatr Infect Dis J 2011; 30(1):e9–e17 |
| CYD08          | 222                     | 222                     | Philippines | San Pablo  | 12–15 m | 01/2010–01/2012 | Mono        | Included     | Crevat et al., Pediatr Infect Dis J, 2015 |
| CYD10          | 35                      | 35                      | Australia | Adelaide    | 18–40 y  | 08/2006–03/2007 | Mono        | Not included | Qiao et al., Am J Trop Med Hyg 2011 |
| CYD11          | 155                     | 155                     | Mexico  | Tixapan Valle de Chalco | 18–45 y | 08/2008–11/2008 | Multi       | Not included | Dayan et al., Hum Vaccin Immunother, 2014 |
| CYD12          | 260                     | 260                     | USA     | New Orleans San Diego Springfield Alabaster Vallejo | 18–45 y | 04/2008–14/2009 | Multi       | Included     | Dayan G et al., Vaccine, 2013 |
| CYD13          | 600                     | 600                     | Colombia Honduras Mexico Puerto Rico | Bucaramanga Tegucigalpa Ternico Carolina | 9–16 y | 10/2009–02/2010 | Multi       | Included     | Villar et al., Pediatr Infect Dis J, 2013 |
| CYD14          | 2000                    | 1994                    | Indonesia Malaysia Philippines Thailand Vietnam | Jakarta Bali Bandung Kuala Lumpur Penang San Pablo City Cebu City Ratchaburi Kampang Phae My Tho Long Xuyen | 2–14 y | 06/2011–12/2011 | Multi       | Included     | Capeding et al., Lancet, 2014 |

Continued
| Study (CYD ID) | Immunosubset (planned) | Immunosubset (analysed) | Country | City/ municipality | Age group | Screening period | Study design | Analyses | References |
|---------------|------------------------|-------------------------|---------|--------------------|-----------|----------------|-------------|---------|------------|
| CYD15         | 2000                   | 1995                    | Brazil  | Vitória            | 9–16 y    | 06/2011–03/2012 | Multi       | Included | Villar et al., N Engl J Med, 2014 |
|               |                        |                         | Colombia | Natal              |           |                |             |         |            |
|               |                        |                         | Honduras | Goiania            |           |                |             |         |            |
|               |                        |                         | Mexico   | Campo Grande       |           |                |             |         |            |
|               |                        |                         | Mexico   | Fortaleza           |           |                |             |         |            |
|               |                        |                         | Mexico   | Yopal              |           |                |             |         |            |
|               |                        |                         | Mexico   | Aguazul            |           |                |             |         |            |
|               |                        |                         | Mexico   | Acacias            |           |                |             |         |            |
|               |                        |                         | Mexico   | Girardot           |           |                |             |         |            |
|               |                        |                         | Mexico   | La Tebaida         |           |                |             |         |            |
|               |                        |                         | Mexico   | Armenia            |           |                |             |         |            |
|               |                        |                         | Mexico   | Calarca            |           |                |             |         |            |
|               |                        |                         | Mexico   | Bucaramanga        |           |                |             |         |            |
|               |                        |                         | Honduras | Tegucigalpa        |           |                |             |         |            |
|               |                        |                         | Honduras | Temixco            |           |                |             |         |            |
|               |                        |                         | Mexico   | Veracruz           |           |                |             |         |            |
|               |                        |                         | Mexico   | Tamaulipas         |           |                |             |         |            |
|               |                        |                         | Mexico   | Tizimin            |           |                |             |         |            |
|               |                        |                         | Mexico   | Valladolid         |           |                |             |         |            |
|               |                        |                         | Mexico   | San Juan Guayama   |           |                |             |         |            |
|               |                        |                         | Mexico   | Guayama            |           |                |             |         |            |
| CYD17         | 715                    | 712                     | Australia| Enoggera           | 18–60 y   | 10/2010–06/2012 | Multi       | Not included | Torresi et al., Vaccine, 2015 |
|               |                        |                         |         | Westmead           |           |                |             |         |            |
|               |                        |                         |         | Herston            |           |                |             |         |            |
|               |                        |                         |         | Carina Heights     |           |                |             |         |            |
|               |                        |                         |         | Adelaide            |           |                |             |         |            |
|               |                        |                         |         | Subiaco            |           |                |             |         |            |
|               |                        |                         |         | Heidelberg         |           |                |             |         |            |
| CYD22         | 252                    | 252                     | Vietnam  | Ho-Chi Minh        | 2–45 y    | 03/2009–07/2009 | Mono        | Included | Tran et al., J Vaccines Vaccin, 2012 |
| CYD23         | 299                    | 299                     | Thailand | Ratchaburi         | 4–11 y    | 02/2009–02/2010 | Mono        | Included | Sabchareon et al., Lancet, 2012 |
| CYD24         | 367                    | 367                     | Peru     | Piura              | 2–11 y    | 09/2008–02/2009 | Mono        | Included | Lanata et al., Vaccine, 2012 |
| CYD28         | 585                    | 585                     | Singapore| Singapore          | 2–45 y    | 04/2009–10/2009 | Multi       | Included | Leo et al., Hum Vaccin Immunother, 2012 |
| CYD29         | 786                    | 784                     | Colombia | Cali               | 12–13 m   | 09/2011–09/2013 | Multi       | Included | Lopez et al., Pediatr Infect Dis J, 2016 |
| CYD30         | 150                    | 150                     | Brazil   | Vitória            | 9–16 y    | 08/2010–10/2010 | Multi       | Included | Dayan et al., Am J Trop Med Hyg, 2013 |

Continued
| Study (CYD ID) | Immunosubset (planned) | Immunosubset (analysed) | Country | City/municipality | Age group | Screening period | Study design | Analyses | References |
|---------------|------------------------|-------------------------|---------|-------------------|-----------|-----------------|-------------|---------|------------|
| CYD32         | 250                    | 250                     | Malaysia | Kuala Lumpur       | 2–11 y    | 12/2010–08/2012 | Multi       | Included | Amar-Singh et al., Vaccine, 2013<sup>18</sup> |
| CYD33         | 714                    | 714                     | Mexico   | Mérida Acapulco Monterrey | 9–12 mm   | 07/2011–06/2013 | Multi       | Included | Rodriguez et al., Pediatr Infect Dis J, 2017<sup>19</sup> |
| CYD47         | 188                    | 188                     | India    | New Delhi Pimpri Ludhiana Bangalore Kalkata | 18–45 y   | 03/2012–02/2014 | Multi       | Included | Dubey et al., Hum Vaccin Immunother, 2015<sup>20</sup> |
| CYD51         | 390                    | 390                     | USA      | Springfield Las Vegas Jacksonville Hoover Mile Fort Detrick | 18–45 y   | 12/2012–11/2013 | Multi       | Not included | Kirstein et al., Submitted for publication |

*mono, single-center; multi, multi-center.*
Sex ratio (male to female) was generally balanced except in Puerto Rico (in the CYD13 study, 0.6:1), India (CYD47, 4.2:1) and the USA (CYD04, 0.3:1). Baseline participant demographic characteristics are shown for each included study by country in supplementary Table S1.

Seropositivity rates
Data were obtained from 8,592 participants overall. Seropositivity rates as measured by PRNT<sub>50</sub> are shown by country, study and age group in Figure 1 and supplementary Table S2.

The Americas
Baseline seropositivity rates and 95% CIs for participants in studies undertaken in the Americas are summarized in Figure 1 (A). Three studies conducted in three different countries enrolled young children, aged <2 years, with seropositivity rates below 11%. Two studies included data for 2–8-year-olds: Mexico in 2006 (CYD06) and Peru (Piura city) in 2008 (CYD24), with seropositivity rates of 2% and 42.6%, respectively. Most of the available data pertained to 9–17-year-olds (five studies in six countries). Seropositivity rates in this age group were relatively high, excluding the USA; these ranged from 53.1% in Mexico in 2011 (CYD15) to 92.4% in Colombia 2011 (CYD15).

In Mexico, variations in baseline seropositivity were observed across studies. The baseline seropositivity rate among participants in the CYD06 study conducted in Mexico City’s metropolitan area (Tlapanta and Valle del Chalco municipalities) in 2006 was low at 2.4%, which contrasted with the higher rates in other Mexican states in 2009 (Morelos, Mexico and Veracruz in CYD13) and 2011 (Morelos, Yucatan, Tamaulipas and Veracruz in CYD15), reported at 54.8% and 53.1% in the two studies, respectively, in the 9–17-year age group.

In countries where different studies were conducted over different time periods in similar age-groups, seropositivity rates were generally not significantly different (overlapping 95% CI).
between the years considered (in 9–17-year-olds in Brazil in 2010 and 2011, in Honduras in 2009 and 2011, in Mexico in 2009 and 2011). However, seropositivity rates in the 9–17-year age group increased between 2009 (CYD13) and 2011 (CYD15) in Colombia (2009: 84.6% [95% CI: 78.4–90.1]; 2011: 92.4% [95% CI: 90.5–94.0]) and decreased in Puerto Rico (CYD13 in 2009: 78.3% [95% CI: 69.2–85.7] vs CYD15 in 2011: 55.9% [95% CI: 47.6–64.0]).

In the 18–45 years age group, low baseline seropositivity rates (10.5% [95% CI: 1.3–33.1]) were reported in Mexico in 2006 (CYD06) as the study was conducted in the non-dengue-endemic area of Mexico City. The seropositivity rate in this age group in the study in the USA in 2005 (CYD04) was 0%.

Asia–Pacific countries

Baseline seropositivity rates and 95% CI for participants in studies undertaken in the Asia–Pacific countries are summarized in Figure 1B. In the one study that included participants aged <2 years the seropositivity rate reported was 42.3% [in the Philippines in 2010 (CYD08)]. Five studies included data for 2–8-year-olds and 9–17-year-olds in six different countries. In 2–8-year-olds, seropositivity rates ranged from 19.8% in Singapore in 2009 (CYD28) to 72.7% in Indonesia in 2011 (CYD14). In 9–17-year-olds, these ranged from 17% in Singapore in 2009 (CYD28) to 91.3% in Indonesia in 2011 (CYD14).

In Malaysia, the Philippines and Vietnam, two different studies were conducted at different time periods in similar age-groups (2–8- and 9–17-year-olds); here also the 95% CI of the seropositivity rates overlapped, indicating no significant differences between the different years considered.

There were three studies in the 18–45-year age group, seropositivity rates were high in Vietnam (94.5% in 2009 [CYD22]) and India (87.2% in 2012 [CYD47]), with lower rates observed in Singapore (48.7% in 2009 [CYD28]).

Proportion of participants who had only experienced primary infection

In studies with data available for both the 2–8 and 9–17-year age groups, the proportion of participants who had only
experienced primary infection was higher in the younger age groups in Peru (22.7% vs 10.6% [CYD24]), the Philippines (22.2% vs 4.6% [CYD14]), Thailand (24.4%–8.5% [CYD23]); and 33.3% vs 7.1% [CYD14]), Vietnam (45.1% vs 15.2% [CYD22]; 36.0% vs 7.5% [CYD14]), Malaysia (45.1% vs 12.9% [CYD32]; 34.0% vs 18.7% [CYD14]), Indonesia (12.0% vs 6.3% [CYD14]) and Singapore (82.0% vs 60.0% [CYD28]; Figure 2 and supplementary Table S3). These proportions remained stable over time (2009 vs 2011) for the same age groups, in Vietnam (22.5% [95% CI: 16.7–29.3] vs 22.2% [95% CI: 16.9–28.2]); CYD22 vs CYD14), Thailand (18.2% [95% CI: 13.2–24.1] vs 19.0% [95% CI: 14.2–24.7]; CYD23 vs CYD14) and Malaysia (36.3% [95% CI: 27.4–45.8] vs 24.1% [95% CI: 17.3–32.0]; CYD32 vs CYD14). Among infants and toddlers (aged <2 years), the proportion who had only experienced primary infection ranged from 62.4% in the Philippines (CYD08) to 82.6% in Colombia (CYD29). In adults, the proportion who had only experienced primary infection, where available, was mostly low (Vietnam: 0% [CYD22], India: 3.0% [CYD47]), except in Singapore where the proportion was 29.0% (CYD28) among 18–45-year-olds (Figure 2B).

Discussion

We determined underlying dengue seropositivity rates in populations encompassing a wide age range, across multiple geographical locations with varying dengue endemicity and temporal settings, using PRNT50 data that were determined at two concordant centralized laboratories following the same validated methodology. We showed that seropositivity rates generally increased with age in endemic settings as a result of cumulative exposure over time. In addition, seropositivity was variable across geographical areas, from one given country to another, but also within a country by locality. However, no major differences were observed for given age groups between the two endemic regions, Latin America and Asia-Pacific, with the exception of Singapore, where lower seropositivity rates were observed in general, relative to other countries in the region. Seropositivity rates were also generally stable over time, where data were available.

Transmission intensity and history of primary infection among populations varied both between and within countries. This phenomenon may have been amplified in our analysis as countries were selected for participation depending on the purpose of the studies to include either low/non endemic (e.g. USA) or endemic areas (e.g. Latin America and Asia-Pacific). Interestingly, some countries like Mexico have regions with different endemicity—the CYD06 study was conducted in an area with very low dengue transmission (Mexico City’s Metropolitan area, at 2240 m above sea level on average and thus with a low vector density), while CYD15 was conducted in highly endemic regions of Mexico. As well as geographic factors, urbanization and the quality of sanitary infrastructures may also have an impact on the extent of vector infestation and, hence, viral circulation. Differences in vector control policies may also contribute to variability in transmission intensities between countries. For example, in the current analysis, we observed lower seropositivity rates in Singapore where effective control measures have been launched, compared with other Asian countries. Conversely, several studies did not find an association between vector indices and dengue seroprevalence.

Dengue virus has circulated in the Asia Pacific region since the 1960s. In 2010, this region accounted for 70% of global disease burden, with co-circulation of the four serotypes in different proportions and with different predominant serotypes. In contrast, Latin American countries experienced a vector re-infestation after the diminution of the yellow fever eradication program in the 1980’s, and serotype distributions vary according to country with patterns observed, from a single predominating serotype to co-circulation of the four serotypes. However, crucially, our seropositivity analysis did not show distinct differences in regional trends between Asia Pacific and Latin America. This is probably due to the persistence and increased intensity of dengue circulation in the absence of efficient vector control measures in Latin American countries in recent decades.

Comparison with other seroprevalence data from literature is difficult due to the limited number of studies conducted to date, and is further limited by the different survey designs and serological tests used. Nevertheless, the same increased trend in seroprevalence with age observed in our study has also been previously reported in surveys conducted in Mexico, Singapore and India. In 2009, a Mexican survey reported a dengue seroprevalence rate of 52.2% in 10–14-year-olds in Morelos, which is consistent with that reported in the CYD13 study (between October 2009 and February 2010)—54.8% in 9–17-year-olds. In Singapore, seroprevalence in 2009 was reported to be between 16.1% and 57.3% in 16–45-year-olds, which is also consistent with that reported in the CYD28 study (17.0–48.7% in 2–45-year-olds) during the same year. In the Indian city of Chennai (east coast), a household-based serosurvey conducted in 2011, reported a seroprevalence rate of 97.3% among 18–45-year-olds, compared with a seroprevalence rate of 87.2% in adults reported in the CYD47 study (between March 2012 and February 2014).

In Colombia, an increase in seropositivity rates between 2009 and 2011 was observed. This was probably due to increased exposure among dengue-naïve individuals during the outbreak of 2010, when 120,918 cases were reported in the Orinoquia region, where the Acacias and Yopal municipalities (CYD15) are located, and the central regions, particularly among those aged under 15 years. In Puerto Rico, in contrast, we observed a decrease in seropositivity rates between 2009 (CYD13) and 2011 (CYD15), despite an outbreak in 2010. During this outbreak, cases were mainly reported in the north of the island, whereas the majority of participants (82%) in CYD15 were from areas in the south-eastern municipality of Guayama. Thus, it is likely that the decrease in seropositivity rate reported in CYD15 relative to CYD13 was due to the inclusion of a high number of participants who were not exposed in the 2010 outbreak. These data reflect the notion that dengue epidemics fluctuate over time—such fluctuation may be due to changes in natural herd immunity, host-virus interactions and virus virulence, as well as heterogeneity in the spatial distribution of the host/vector populations and climatic shift.

We observed that the proportion of participants who had only experienced primary infection tended to be higher in the younger age groups than in adolescents and adults. This is indicative...
of the limited cumulative dengue-exposure in the younger age group. It also corroborates observation that seroprevalence increases with age, with age being a surrogate for cumulative exposure. Comparison with data from the literature is also difficult because of the lack of data and limited temporal correspondence. However, a dynamic school-based study of a cohort of Vietnamese children aged 2–15 years, which used IgG seroconversion to determine annual seroprevalence, reported the same stable trend over time for the proportion who had only experienced primary infection among given age groups as observed in the CYD studies where temporal data were available. Although not directly comparable with our study, between 2004 and 2007, the school-based cohort study revealed an average annual crude incidence risk of primary infection equal to 11.4% (range: 7.9–13.6%).58 The rarer, but evident occurrence of adults living in endemic countries who have only experienced a primary infection may be explained by low virus circulation in some areas within these countries; this may simply reflect the geographical variability in the burden of dengue within these endemic countries.

Limitations of these analyses arise mainly from the fact that selected participants in the vaccine trials may not be representative of the respective nationwide populations from which the trials were undertaken:

- sites were not randomly selected;
- limited age groups were represented in some studies, in particular in Latin America.

Although the strict definition of primary infection used here ensured the detection of definitive primary infections only, this may lead to an under or over estimation of the true primary rate. For instance, when the serum sample is taken shortly after primary infection, responses against multiple serotypes can be observed.59 However, in countries of low endemicity with large time intervals between epidemics, PRNT titers may wane with time in the absence of natural boosting, and neutralizing antibody responses detectable against only one serotype may be observed despite the overall multitypic dengue exposure profile. In addition, the numbers of seropositive samples in our analysis were sometimes too small to permit accurate determination of observed rates and meaningful comparisons with other studies. Flavivirus-induced antibody cross-reactivity exists due to antigenic epitopes common to flaviviruses and may result in some false positives, where the viruses co-circulate or as a result of vaccination. However, there is no evidence to date that yellow fever vaccination could influence dengue PRNT results, as observed with DENV-2.60 In addition, the studies undertaken in Latin America were started prior to Zika introduction and circulation in the region.61

**Conclusions**

This study is the first to provide a consistently derived overview of dengue seropositivity data from different countries, at different times, using a validated neutralization assay at centralized laboratories. With such a unique dataset per country and over time, these results represent the largest collection to date of comparable standardized dengue seropositivity data across countries. Given that the majority of dengue infections are clinically asymptomatic, and that the disease is greatly underreported, these results provide distinctive information on dengue transmission per age group in the 14 participating countries, and will be invaluable in future modeling studies that explore the temporal and spatial distribution of dengue infection. Together with information on the characteristics of vector, virus and host populations, information on seroprevalence helps to determine the exposure history of populations, and the temporal and spatial dynamic of virus circulation. These results will help define the level of dengue endemcity, a key factor in informing and guiding dengue control strategies.

**Supplementary data**

Supplementary data are available at Transactions online (http://trstmh.oxfordjournals.org/).

**Author contributions:** ML, JA, KF and NJ conceived and designed the analyses. The data was analyzed by JA KF ML EP, MB, AB, CF, FN, BZ, RLO and BG contributed to acquisition and interpretation of data. The paper was drafted by ML, JA, BG and NJ. All authors participated in revising and finalizing the manuscript.

**Acknowledgements:** The authors would like to thank all the participants and their parents/guardians who participated in the studies, the investigators, the study sites staff, and Sanofi Pasteur colleagues, including Valentine Delore, for technical inputs; Médric Celle and Etienne Gransard, for providing the dataset; and Laurent Coudeville, Joshua Nealon and Gee Marsh, for their input during manuscript development. Editorial assistance with the preparation of the manuscript was provided by Richard Glover, inScience Communications, Springer Healthcare, Chester, UK. The authors would also like to thank Jean-Sébastien Persico for editorial assistance and manuscript coordination on behalf of Sanofi Pasteur.

**Funding:** This work was supported by Sanofi Pasteur.

**Conflict of interest:** All the authors are employees of Sanofi Pasteur.

**Ethical approval:** All studies included in this analysis were performed in accordance with the Declaration of Helsinki and the International Conference on Harmonization—Good Clinical Practice. Study protocols and amendments were approved by the individual review board/independent ethics committee for each participating site. All participants or their parents/guardians provided informed written consent.

**References**

1. Brady OJ, Gething PW, Bhatt S et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis 2012;6(8):e1760.
2. Bhatt S, Gething PW, Brady OJ et al. The global distribution and burden of dengue. Nature 2013;496(7446):504–7.
3. World Health Organization. Dengue: guidelines for treatment, prevention and control. 2009. http://www.who.int/tdr/publications/documents/dengue-diagnosis.pdf [accessed 21 March 2017].
4 Heinz FX, Stiasny K. Flaviviruses and flavivirus vaccines. Vaccine 2012;30(29):4301–6.
5 Simmons CP, Farrar JJ, Nguyen vV et al. Dengue. N Engl J Med 2012;366(15):1423–32.
6 Gubler DJ. How effectively is epidemiological surveillance used for dengue programme planning and epidemic response? Dengue Bull 2002;26:96–106.
7 Ooi EE, Gubler DJ, Nam VS. Dengue research needs related to surveillance and emergency response. Report of the Scientific Working Group Meeting on Dengue, Geneva, 1–5 October 2006:124–33.
8 Deen JL, Harris E, Wills B et al. The WHO dengue classification and case definitions: time for a reassessment. Lancet 2006;368(9530):170–3.
9 Ooi EE, Gubler DJ. Dengue in Southeast Asia: epidemiological characteristics and strategic challenges in disease prevention. Cad Saude Publ 2009;25(Suppl 1):S115–24.
10 Gomez-Dantes H, Willaquet JR. Dengue in the Americas: challenges for prevention and control. Cad Saude Publ 2009;25(Suppl 1):S19–31.
11 Nealon J, Taurel AF, Capeding MR et al. Symptomatic dengue disease in five southeast Asian countries: epidemiological evidence from a dengue vaccine trial. PLoS Negl Trop Dis 2016;10(8):e0004918.
12 Sarti E, L’Azuou M, Mercado M et al. A comparative study on active and passive epidemiological surveillance for dengue in five countries of Latin America. Int J Infect Dis 2016;44:44–9.
13 Olivera-Botello G, Coudeville L, Fanouillere K et al. Tetravalent dengue vaccine reduces symptomatic and asymptomatic dengue virus infections in healthy children and adolescents aged 2–16 years in Asia and Latin America. J Infect Dis 2016;214(7):994–1000.
14 Anders KL, Le Hong Nga NTN, Van Thuy NT et al. Households as foci for dengue transmission in highly urban Vietnam. PLoS Negl Trop Dis 2015;9(2):e0003528–e0003528.
15 World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization, April 2016—conclusions and recommendations. Wkly Epidemiol Rec 2016;91(21):266–84.
16 Hadinegoro SR, Arredondo-Garcia JL, Capeding MR et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015;373(13):1195–206.
17 Imai N, Dorigatti I, Cauchemez S et al. Estimating dengue transmission intensity from sero-prevalence surveys in multiple countries. PLoS Negl Trop Dis 2015;9(4):e0003719.
18 Koraka P, Zeller H, Niedrig M et al. Reactivity of serum samples from patients with a flavivirus infection measured by immunofluorescence assay and ELISA. Microbes Infect 2002;4(4):1209–15.
19 Edelman R, Hornbach J. Guidelines for the clinical evaluation of dengue vaccines in endemic areas: summary of a World Health Organization technical consultation. Vaccine 2008;26(33):4113–19.
20 Timiryasova TM, Bonaparte MI, Luo P et al. Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development. Am J Trop Med Hyg 2013;88(5):962–70.
21 Guirakhoo F, Kitchener S, Morrison D et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccines 2006;2(2):60–7.
22 Morrison D, Legg TJ, Billings CW et al. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 2010;201(3):370–7.
23 Capeding RZ, Luna IA, Bomasang E et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 2011;29(22):3863–72.
24 Crevat D, Brion JD, Gailhardou S et al. First experience of concomitant vaccination against dengue and MMR in toddlers. Pediatr Infect Dis J 2015;34(8):884–92.
25 Qiao M, Shaw D, Forrat R et al. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am J Trop Med Hyg 2011;85(4):724–31.
26 Dayan GH, Galan-Herrera JF, Forrat R et al. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naive adults in Mexico. Hum Vaccin Immunother 2014;10(10):2853–63.
27 Dayan GH, Thakur M, Boaz M et al. Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA. Vaccine 2013;31(44):5047–54.
28 Villar LA, Rivera-Medina DM, Arredondo-Garcia JL et al. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9–16 year olds: a randomized, controlled, phase II trial in Latin America. Pediatr Infect Dis J 2013;32(10):1102–9.
29 Capeding MR, Tran NH, Hadinegoro SR et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014;384(9951):1358–65.
30 Villar L, Dayan GH, Arredondo-Garcia JL et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015;372(2):113–23.
31 Torresi J, Heron LG, Qiao M et al. Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study. Vaccine 2015;33(39):5127–34.
32 Tran N, Luong C, Vu T et al. Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) in healthy Vietnamese adults and children. J Vaccines Vaccine 2012;3(162):2.
33 Sabcharoen A, Wallace D, Sirivichayakul C et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012;380(9853):1559–67.
34 Lanata CF, Andrade T, Gil AI et al. Immunogenicity and safety of tetravalent dengue vaccine in 2–11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. Vaccine 2012;30(41):5935–41.
35 Leo YS, Wilder-Smith A, Archuleta S et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 y: Phase II randomized controlled trial in Singapore. Hum Vaccin Immunother 2012;8(9):1259–71.
36 Lopez P, Lanata CF, Zambrano B et al. Immunogenicity and safety of yellow fever vaccine (Stamaril) when administered concomitantly with a tetravalent dengue vaccine candidate in healthy toddlers at 12–13 months of age in Colombia and Peru: a randomized trial. Pediatr Infect Dis J 2016;35(10):1140–7.
37 Dayan GH, Garbes P, Noriega F et al. Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9–16 years in Brazil. Am J Trop Med Hyg 2013;89(6):1058–65.
38 His S, Koh MT, Tan KK et al. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2–11 years in Malaysia: a randomized, placebo-controlled, Phase III study. Vaccine 2013;31(49):5814–21.
39 Rodriguez Melo FJ, Morales JJ, De Los Santos AH et al. Immunogenicity and safety of a booster injection of DTap-IPV//Hib (Pentaxim(R)) administered concomitantly with tetravalent dengue vaccine in healthy toddlers aged 15 to 18 months in Mexico: a randomized trial. Pediatr Infect Dis J 2017;36(6):602–08.
40 Dubey AP, Agarkhedkar S, Chhatwal J et al. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: a randomized, observer-blind, placebo-controlled phase II trial. Hum Vaccin Immunother 2016;12(2):0512–8.

41 Roehrig JT, Hombach J, Barrett AD. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 2008;21(2):123–32.

42 Tsai WY, Durbin A, Tsai JJ et al. Complexity of neutralizing antibodies against multiple dengue virus serotypes after heterotypic immunization and secondary infection revealed by in-depth analysis of cross-reactive antibodies. J Virol 2015;89(14):7348–62.

43 Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26(4):404–13.

44 Wilder-Smith A, Foo W, Earnest A et al. Seroepidemiology of dengue in the adult population of Singapore. Trop Med Int Health 2004;9(2):305–8.

45 Thammapalo S, Chongsuvivatwong V, Geater A et al. Environmental factors and incidence of dengue fever and dengue hemorrhagic fever in an urban area, Southern Thailand. Epidemiol Infect 2008;136(1):135–43.

46 Honorio NA, Nogueira RM, Codeco CT et al. Spatial evaluation and modeling of dengue seroprevalence and vector density in Rio de Janeiro, Brazil. PLoS Negl Trop Dis 2009;3(11):e545.

47 L’Azou M, Moureau A, Sarti E et al. Symptomatic dengue in children in 10 Asian and Latin American countries. N Engl J Med 2016;374(12):1155–66.

48 Halstead SB. Dengue in the Americas and Southeast Asia: do they differ? Rev Panam Salud Publica 2006;20(6):407–15.

49 Navarrete-Espinosa J, Acevedo-Vales JA, Huerta-Hernandez E et al. Prevalence of dengue and leptospirosis antibodies in the state of Veracruz, Mexico. Salud Publ Mex 2006;48(3):220–8.

50 Ramos MM, Mohammed H, Zielinski-Gutierrez E et al. Epidemic dengue and dengue hemorrhagic fever at the Texas-Mexico border: results of a household-based seroepidemiologic survey, December 2005. Am J Trop Med Hyg 2008;78(3):364–9.

51 Amaya-Larios IY, Martinez-Vega RA, Mayer SV et al. Seroprevalence of neutralizing antibodies against dengue virus in two localities in the state of Morelos, Mexico. Am J Trop Med Hyg 2014;91(5):1057–65.

52 Yew YW, Ye T, Ang LW et al. Seroepidemiology of dengue virus infection among adults in Singapore. Ann Acad Med Singapore 2009;38(8):667–75.

53 Yap G, Li C, Mutalib A et al. High rates of apparent dengue in older adults in Singapore. Am J Trop Med Hyg 2013;88(6):1065–9.

54 Low SL, Lam S, Wong WY et al. Dengue seroprevalence of healthy adults in Singapore: serosurvey among blood donors, 2009. Am J Trop Med Hyg 2015;93(1):40–5.

55 Rodriguez-Barracaer I, Solomon SS, Kuganantham P et al. The hidden burden of dengue and chikungunya in Chennai, India. PLoS Negl Trop Dis 2015;9(7):e0003906.

56 Villar LA, Rojas DP, Besada-Lombana S et al. Epidemiological trends of dengue disease in Colombia (2000–2011): a systematic review. PLoS Negl Trop Dis 2015;9(3):e0003499.

57 Sharp TM, Hunsperger E, Santiago GA et al. Virus-specific differences in rates of disease during the 2010 dengue epidemic in Puerto Rico. PLoS Negl Trop Dis 2013;7(4):e2159.

58 Tien NT, Luxemburger C, Toan NT et al. A prospective cohort study of dengue infection in schoolchildren in Long Xuyen, Viet Nam. Trans R Soc Trop Med Hyg 2010;104(9):592–600.

59 van Panhuis WG, Gibbons RV, Endy TP et al. Inferring the serotype associated with dengue virus infections on the basis of pre- and postinfection neutralizing antibody titers. J Infect Dis 2010;202(7):1002–10.

60 Mansfield KL, Horton DL, Johnson N et al. Flavivirus-induced antibody cross-reactivity. J Gen Virol 2011;92(Pt 12):2821–9.

61 Lee WT, Wong SJ, Kulas KE et al. Development of zika virus serological testing strategies in New York State. J Clin Microbiol 2018;56(3).